A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

PFS

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

.≥65 years or PS 2

• Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small cell lung cancer

• Patients received no chemical therapy or only received targeted therapy,and there is evidence show the patent is PD

• Presence of at least one index lesion measurable by CT scan or MRI

• leucocyte ≥ 3.5×109/L

• neutrophil ≥ 1.5×109/L

• platelet ≥ 80×109/L

• Hemoglobin ≥ 9g/L

• ALT and AST ≤ 2.5×ULN ,Tbil≤ 1.5×ULN

• BUN≤ 1.5×ULN

• Signed written informed consent

Exclusion Criteria:

• squamous carcinoma or small cell lung cancer

• Patients were allergic to pemetrexed

• Patients received chemotherapy before

• Uncontrolled acute infection

.Uncontrolled pleural effusion

• Severe symptomatic heart disease

• Severe infection or metabolic disfunction

• Patients with other malignant tumor

• Uncontrolled brain metastases

• Patients have accepted other clinical trials

• Female patients during their pregnant and lactation period, or patients without contraception

• Mental disorientation of disorder

• Glucocorticoids taboo